Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 3011-3018

  Jendrek, Scott ^a   Little, Stephen F ^b   Hem, Stanley ^c   Mitra, Gautam ^a   Giardina, Steven ^a  

^a SAIC FREDERICK INC   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Aluminum containing adjuvant; Anthrax; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ANTHRAX VACCINE; BUFFER; EDETIC ACID; IMMUNOLOGICAL ADJUVANT; RECOMBINANT PROTECTIVE ANTIGEN VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANTIGEN BINDING; ARTICLE; CALCULATION; CONTROLLED STUDY; CYTOTOXICITY; DESORPTION; DRUG ACTIVITY; DRUG ADSORPTION; DRUG BINDING; ELECTRICITY; ELUTION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE;

EID: 0038173808     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00109-9     Document Type: Article

References (23)

1. Koch R. The aetiology of anthrax based on the ontogeny of the anthrax bacillus. Med. Classics. 2:1937;787.
2. Modlin JF (Chairman). Use of anthrax vaccine in the United States. Recommendation of the Advisory Committee on Immunization Practices. Morbidity Mortality Weekly Rep 2000 Dec 15.
3. Advisory Committee for Immunization Practices. Adult Immunization. Morbidity Mortality Weekly Rep 1984;33:33-4.
4. Turnbill P.C.B., Broster M.G., Carman J.A., Manchee R.J., Melling J. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:1986;356-363.
5. Brachman P.S., Gold H., Plotkin S.A., Fekety F.R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Public Health. 52:1962;632-645.
6. Ivins BE, Fellows PF, Pitt MLM, Estep JE, Welkos SL, Worsham PL, et al. Efficacy of a standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. In: Proceedings of the International Workshop on Anthrax, 1995 Sept 19-21; Winchester, UK. Salisbury Med Bull 1990;(Suppl 68):125-6.
7. Farchaus J.W., Ribot W.J., Jendrek S., Little S.F. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl. Environ. Microbiol. 64:1998;982-991.
8. Ivins B.E., Pitt M.L.M., Fellows P.F., Farchaus J.W., Benner G.E., Waag D.M.et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine. 16:1998;1141-1148.
9. Edelman R. An overview of adjuvant use. Vaccine adjuvants: preperation methods and research protcols. Methods Mol Med 2000;42.
10. Ivins BE, Farchaus JW, Novak J, Pitt ML, Fellows PF, Ribot WJ, et al. Vaccine efficacy of Bacillus anthracis protective antigen produced in prokaryotic and eukaryotic cells. In: Abstracts of the 94th General Meeting of the American Society for Microbiology 1994, Washington, DC. Am Soc Microbiol 1994;E-38:150 [Abstract].
11. Ivins B.E., Fellows P.F., Pitt L., Estep J., Farchaus J., Friedlander A.et al. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine. 13:1995;1779-1784.
12. Pitt MLM, Ivins BE, Estep JE, Farchaus J, Friedlander AM. Comparison of the efficacy of the purified protective antigen and MDPH to protect nonhuman primates from inhalation anthrax. In: Turnbull PC, editor. Proceedings of the International Workshop on Anthrax, 1995 Sept 19-21; Winchester, UK. Salisbury Med Bull 1996;(Suppl 87):130.
13. Rinella JR Jr, White JL, Hem SL. Effect of pH on the elution of model antigens from aluminum-containing adjuvants. J Colloid Interface Sci 1998;205:161-5.
14. Seeber S.J., White J.L., Hem S.L. Predicting the adsortion of proteins by aluminum-containing adjuvants. Vaccine. 9:1991;201-203.
15. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines - US perspective. Vaccine. 20:2002;818-823.
16. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods. 119:1989;203-210.
17. Martin A. Physical pharmacy. 4th ed. Philadelphia: Lea & Febiger, 1993. p. 282-3.
18. Heimlich J.M., Regnier F.E., White J.L., Hem S.L. The in vitro displacement of adsorbed model antigens from aluminium-containing adjuvants by interstitial fluid. Vaccine. 17:1999;2873-2881.
19. Iyer S., HogenEsch H., Hem S.L. Effect of the degree of phosphate substitution in aluminum hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm. Dev. Technol. 8:2003;81-86.
20. Chang M.-F., White J.L., Nail S.L., Hem S.L. Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant. PDA J. Pharm. Sci. Technol. 51:1997;1-5.
21. Callahan P.M., Shorter A.L., Hem S.L. The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm. Res. 8:1991;851-857.
22. Rinella J.R. Jr., White J.L., Hem S.L. Effect of anions on model aluminum-adjuvant-containing vaccines. J. Colloid Interface Sci. 172:1994;121-130.
23. Gupta RK, Rost BF, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. In: Powell MF, Newman MJ, editors. Vaccine design: the subunit and adjuvant approach. New York: Plenum Press; 1995.